• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Abbott (ABT) Is Up 7.4% After Mixed Q2 Results And Expanded Heart Device, Diagnostics Push

    Simply Wall St·07/30/2026 13:20:53
    Listen to the news
    • Abbott Laboratories recently reported second-quarter 2026 results showing sales rising to US$12,593 million from US$11,142 million a year earlier, while net income fell to US$928 million and diluted EPS from continuing operations slipped to US$0.53 from US$1.01.
    • At the same time, Abbott is strengthening its medical device and diagnostics portfolio with a large real-world TriClip heart valve study and ongoing expansion in diabetes and oncology testing, which could reshape how investors view its long-term healthcare footprint despite weaker profitability.
    • We’ll now examine how the new real-world TriClip study could influence Abbott’s investment narrative and future growth assumptions.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Abbott Laboratories Investment Narrative Recap

    To hold Abbott today, I think you need to believe that its broad healthcare portfolio, particularly in devices and diagnostics, can offset softer profitability and margin pressure. The latest quarter showed higher sales but sharply lower earnings, so in my view the key short term catalyst is execution in higher value devices like structural heart, while the biggest risk remains pricing and margin pressure in diagnostics and diabetes if competition and procurement headwinds persist. The new TriClip real world study does not materially change that near term balance.

    Among recent announcements, the CE Mark for Abbott’s Libre Duo dual glucose ketone sensor stands out alongside TriClip as part of the same theme: pushing deeper into chronic disease management with next generation devices. For investors watching catalysts, these launches and clinical programs sit directly against risks around commoditization and competitive bidding in continuous glucose monitoring, because product differentiation and real world data can influence how resilient pricing and volumes prove to be over time.

    Yet despite the appeal of new devices, investors should still be aware of the growing pressure on margins and pricing in Abbott’s diagnostics and diabetes businesses...

    Read the full narrative on Abbott Laboratories (it's free!)

    Abbott Laboratories’ narrative projects $60.4 billion revenue and $9.5 billion earnings by 2029. This requires 9.0% yearly revenue growth and about a $4.1 billion earnings increase from $5.4 billion today.

    Uncover how Abbott Laboratories' forecasts yield a $119.12 fair value, a 10% upside to its current price.

    Exploring Other Perspectives

    ABT 1-Year Stock Price Chart
    ABT 1-Year Stock Price Chart

    Five members of the Simply Wall St Community currently place Abbott’s fair value between US$118.42 and US$148.32, highlighting how far opinions can spread. When you set those views against ongoing concerns about pricing pressure and margin headwinds in diagnostics, it underlines why it is worth comparing several different takes on Abbott’s longer term earnings power before deciding how you feel about the stock.

    Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth as much as 37% more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready To Venture Into Other Investment Styles?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.